These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19688186)

  • 21. Recent developments in nanocarrier-aided mucosal vaccination.
    Kammona O; Bourganis V; Karamanidou T; Kiparissides C
    Nanomedicine (Lond); 2017 May; 12(9):1057-1074. PubMed ID: 28440707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Microfold cells-targeting antigen delivery: a promising strategy to enhance the efficacy of mucosal vaccines].
    Wang Y; Li M; Sun Y; Qiu HJ
    Sheng Wu Gong Cheng Xue Bao; 2019 Feb; 35(2):216-225. PubMed ID: 30806051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccines, adjuvants and key factors for mucosal immune response.
    Correa VA; Portilho AI; De Gaspari E
    Immunology; 2022 Oct; 167(2):124-138. PubMed ID: 35751397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanocarriers: a versatile approach for mucosal vaccine delivery.
    Mody N; Sharma R; Agrawal U; Vyas SP
    Ther Deliv; 2015 Feb; 6(2):231-45. PubMed ID: 25690089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies for optimizing targeting and delivery of mucosal HIV vaccines.
    Ahlers JD; Belyakov IM
    Eur J Immunol; 2009 Oct; 39(10):2657-69. PubMed ID: 19609978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.
    Royer DJ; Carr MM; Gurung HR; Halford WP; Carr DJJ
    J Immunol; 2017 Sep; 199(5):1898-1911. PubMed ID: 28760885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New advances in mucosal vaccination.
    Ranasinghe C
    Immunol Lett; 2014 Oct; 161(2):204-6. PubMed ID: 24462961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery.
    Wang SH; Thompson AL; Hickey AJ; Staats HF
    Curr Top Microbiol Immunol; 2012; 354():121-56. PubMed ID: 21822816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucosal and systemic responses of immunogenic vaccines candidates against enteric Escherichia coli infections in ruminants: A review.
    Lawan A; Jesse FFA; Idris UH; Odhah MN; Arsalan M; Muhammad NA; Bhutto KR; Peter ID; Abraham GA; Wahid AH; Mohd-Azmi ML; Zamri-Saad M
    Microb Pathog; 2018 Apr; 117():175-183. PubMed ID: 29471137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Jump-starting the immune system: prime-boosting comes of age.
    Woodland DL
    Trends Immunol; 2004 Feb; 25(2):98-104. PubMed ID: 15102369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
    Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
    APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.
    Boyaka PN
    J Immunol; 2017 Jul; 199(1):9-16. PubMed ID: 28630108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innate endogenous adjuvants prime to desirable immune responses via mucosal routes.
    Wang X; Meng D
    Protein Cell; 2015 Mar; 6(3):170-84. PubMed ID: 25503634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa.
    Cox E; Verdonck F; Vanrompay D; Goddeeris B
    Vet Res; 2006; 37(3):511-39. PubMed ID: 16611561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defensive Driving: Directing HIV-1 Vaccine-Induced Humoral Immunity to the Mucosa with Chemokine Adjuvants.
    Gary EN; Kutzler MA
    J Immunol Res; 2018; 2018():3734207. PubMed ID: 30648120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of B cells by a dendritic cell-targeted oral vaccine.
    Sahay B; Owen JL; Yang T; Zadeh M; Lightfoot YL; Ge JW; Mohamadzadeh M
    Curr Pharm Biotechnol; 2013; 14(10):867-77. PubMed ID: 24372255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucosal Vaccine Development Based on Liposome Technology.
    Bernasconi V; Norling K; Bally M; Höök F; Lycke NY
    J Immunol Res; 2016; 2016():5482087. PubMed ID: 28127567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delivery strategies to enhance mucosal vaccination.
    Chadwick S; Kriegel C; Amiji M
    Expert Opin Biol Ther; 2009 Apr; 9(4):427-40. PubMed ID: 19344280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.